NEWS HIGHLIGHTSMedia Articles Related to Lantus (Insulin Glargine)
Canadian study demonstrates new approach to achieving diabetes control
Source: The Doctors Lounge - Endocrinology and Diabetes
The INSIGHT study demonstrates early addition of insulin glargine therapy safely achieved better glycemic than adding oral agents.
Published Studies Related to Lantus (Insulin Glargine)
Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. [2011.11.08]
Minicucci L, Haupt M, Casciaro R, De Alessandri A, Bagnasco F, Lucidi V, Notarnicola S, Lorini R, Bertasi S, Raia V, Cialdella P, Haupt R. Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial... Further studies are necessary to test glargine at higher dosage and for a longer follow-up period.
Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. [2011.11]
AIM: Stepwise intensification of insulin treatment to match the progressive decline of endogenous insulin secretion has been shown to be an effective management strategy in type 2 diabetes mellitus (T2DM). The efficacy of initiating and titrating a single bolus dose of insulin glulisine to baseline insulin glargine plus oral hypoglycaemic agents (OHAs) was investigated... CONCLUSIONS: In people with T2DM inadequately controlled on basal insulin plus OHAs, adding a single injection of insulin glulisine prior to the main meal significantly improves glucose control without undesired side effects. (c) 2011 Blackwell Publishing Ltd.
Insulin injections in relation to meals in the hospital medicine ward: comparison of 2 protocols. [2011.09.01]
OBJECTIVE: To investigate whether changing the prandial regular insulin to rapid-acting insulin analogue in hospital medicine wards improves the timing of insulin delivery in relation to meals and improves patient safety and glucose control... CONCLUSIONS: The use of prandial insulin analogues in medicine wards allows better timing with meals than regular insulin and results in better hypoglycemic outcomes. Higher rates of hyperglycemia with prandial analogues may need adjustment in insulin doses.
Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor alpha are attenuated by prandial + basal insulin in patients with Type 2 diabetes. [2011.09]
AIM: To determine if a regimen with prandial + basal insulin compared with basal insulin attenuates post-meal inflammatory and glycative biomarkers in patients with Type 2 diabetes... CONCLUSIONS: Controlling post-meal hyperglycaemia with prandial + basal insulin in patients with Type 2 diabetes attenuates meal-induced increases in high-sensitivity C-reactive protein, interleukin-6 and tumour necrosis factor alpha compared with basal insulin. The rise in post-meal glucose, but not triglycerides, significantly correlated with the rise in post-meal inflammatory and glycative biomarkers. (c) 2011 The Authors. Diabetic Medicine (c) 2011 Diabetes UK.
[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus]. [2011.08]
BACKGROUND AND OBJECTIVES: Exenatide, a GLP-1 receptor agonist for adjuvant treatment of type 2 diabetes mellitus (T2DM), has been shown to be as effective as insulin glargine (IG) for reducing glycated hemoglobin levels combined with metformin or/and sulphonylureas. Exenatide is associated to weight reduction and a higher incidence of gastrointestinal adverse events. The objective of this study was to assess the cost-effectiveness of exenatide as compared to IG in obese patients with T2DM not achieving an adequate blood glucose control from the perspective of the Spanish healthcare system... CONCLUSIONS: Exenatide was associated to greater clinical benefits and higher costs in obese T2DM patients as compared to IG. Considering a willingness-to-pay threshold of euro 30,000 per QALY gained in the Spanish setting, exenatide represents an efficient option in comparison with IG. Copyright (c) 2010 SEEN. Published by Elsevier Espana. All rights reserved.
Clinical Trials Related to Lantus (Insulin Glargine)
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-Study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial) [Completed]
Primary objective:
AT. LANTUS main study*
- To determine the optimal treatment algorithm for insulin glargine based on the incidence
of severe hypoglycaemia.(*Target Number of patients for the main study: 2346)
HALT Sub-study**
- To test the hypothesis that titration regimens involving insulin glargine are associated
with changes in the rate of symptomatic hypoglycaemic episodes together with changes in
Fear of Hypoglycaemia as measured by the HFS-98 Questionnaire in Type I
diabetes.(**Target Number of patients for the Sub-study: 250)
Secondary objectives:
AT. LANTUS main study
To determine:
- the incidence of symptomatic, asymptomatic and nocturnal hypoglycaemia with each
treatment regimen
- the difference in glycemic control as measured by HbA1c and fasting blood glucose with
each treatment regimen
- the difference in glycemic control as measured by HbA1c and fasting blood glucose
between baseline and end of treatment
- the safety on the use of insulin glargine in each treatment algorithm
- the change in subject weight with each treatment regimen
- the change in insulin doses with each treatment regimen
- the change in Diabetes Treatment Satisfaction (Diabetes Treatment Satisfaction
Questionnaire, sub-study only) with each treatment regimen
HALT Sub-study (baseline to study end)
- To estimate the relationship between change in HbA1c and incidence of hypoglycaemia
- To examine the effect of insulin glargine on Quality of Life (EQ-5D) in relation to
incidence of hypoglycaemia
- To examine the effect of insulin glargine on the Hospital Anxiety and Depression Scale
(HADS) in relation to the incidence of hypoglycaemia
- To examine the use of the Prescription Plan versus standard management (no Prescription
Plan)
Lantus in Prediabetes [Completed]
Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus [Completed]
To introduce initiation of glargine insulin treatment in primary care based on a patient
education program. To show and compare feasibility of group education to individual education
program.
Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil) [Completed]
To estimate the efficacy of combination therapy with Lantus plus Amaryl in controlling blood
glucose in Japanese patients with type 2 diabetes having failed OAD therapy, and document the
ability to preserve the endocrine pancreatic function with Lantus plus Amaryl combination
therapy
Euglycemic Clamp Dose-response Study Comparing Insulin Glargine U300 With Lantus® U100 [Recruiting]
Reports of Suspected Lantus (Insulin Glargine) Side Effects
Device Malfunction (462),
Blood Glucose Increased (396),
Product Quality Issue (272),
Hyperglycaemia (254),
Hypoglycaemia (240),
Cerebrovascular Accident (109),
Death (103),
Blood Glucose Decreased (101),
Fall (90),
Renal Failure (90), more >>
|
